Advanced Search

Study Preview



Study Title and Description

Xylooligosaccharide increases bifidobacteria but not lactobacilli in human gut microbiota.



Key Questions Addressed
1 Is this a fiber intervention study?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Xylooligosaccharide increases bifidobacteria but not lactobacilli in human gut microbiota.
Author Finegold SM., Li Z., Summanen PH., Downes J., Thames G., Corbett K., Dowd S., Krak M., Heber D.
Country Infectious Diseases Section, VA Medical Center West Los Angeles, 11301 Wilshire Blvd., Los Angeles, CA 90073, USA. sidfinegold@gmail.com.
Year 2014
Numbers Pubmed ID: 24513849

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Fiber 5.0
Arms
No arms have been defined in this extraction form.

Design Details
Question... Follow Up Answer Follow-up Answer
Version 4.0
  • Comments Comments (
    0
    ) |
pubyear 2014
  • Comments Comments (
    0
    ) |
country United States
  • Comments Comments (
    0
    ) |
design Randomized Controlled Trial (parallel)
  • Comments Comments (
    0
    ) |
blindness Double blind
  • Comments Comments (
    0
    ) |
diet Unspecified
  • Comments Comments (
    0
    ) |
feedcontrol Food partially provided
  • Comments Comments (
    0
    ) |
sampsize 32
  • Comments Comments (
    0
    ) |
runin Yes
  • Comments Comments (
    0
    ) |
washout Yes
  • Comments Comments (
    0
    ) |
dosechange No
  • Comments Comments (
    0
    ) |
age_adult 1
  • Comments Comments (
    0
    ) |
age_adol
  • Comments Comments (
    0
    ) |
age_child
  • Comments Comments (
    0
    ) |
age_baby
  • Comments Comments (
    0
    ) |
age_infant
  • Comments Comments (
    0
    ) |
age_oth
  • Comments Comments (
    0
    ) |
age_mean ~32.4
  • Comments Comments (
    0
    ) |
age_range 21-49
  • Comments Comments (
    0
    ) |
bmi_mean ~24.6
  • Comments Comments (
    0
    ) |
bmi_range
  • Comments Comments (
    0
    ) |
blhealth_healthy 1
  • Comments Comments (
    0
    ) |
blhealth_hyperlip
  • Comments Comments (
    0
    ) |
blhealth_diab
  • Comments Comments (
    0
    ) |
blhealth_hyperten
  • Comments Comments (
    0
    ) |
blhealth_digest
  • Comments Comments (
    0
    ) |
blhealth_met
  • Comments Comments (
    0
    ) |
blhealth_oth
  • Comments Comments (
    0
    ) |
blhealth_othspec
  • Comments Comments (
    0
    ) |
gender ~34.4
  • Comments Comments (
    0
    ) |
ftype1 Xylo-Oligosaccharide
  • Comments Comments (
    0
    ) |
descrip1_1
  • Comments Comments (
    0
    ) |
descrip1_2
  • Comments Comments (
    0
    ) |
dose1_1 1.4
  • Comments Comments (
    0
    ) |
dose1_2
  • Comments Comments (
    0
    ) |
duration1 8 weeks
  • Comments Comments (
    0
    ) |
admin1 Tablet
  • Comments Comments (
    0
    ) |
ftype2 Xylo-Oligosaccharide
  • Comments Comments (
    0
    ) |
descrip2_1
  • Comments Comments (
    0
    ) |
descrip2_2
  • Comments Comments (
    0
    ) |
dose2_1 2.8
  • Comments Comments (
    0
    ) |
dose2_2
  • Comments Comments (
    0
    ) |
duration2 8 weeks
  • Comments Comments (
    0
    ) |
admin2 Tablet
  • Comments Comments (
    0
    ) |
ftype3
  • Comments Comments (
    0
    ) |
descrip3_1
  • Comments Comments (
    0
    ) |
descrip3_2
  • Comments Comments (
    0
    ) |
dose3_1
  • Comments Comments (
    0
    ) |
dose3_2
  • Comments Comments (
    0
    ) |
duration3
  • Comments Comments (
    0
    ) |
admin3
  • Comments Comments (
    0
    ) |
ftype4
  • Comments Comments (
    0
    ) |
descrip4_1
  • Comments Comments (
    0
    ) |
descrip4_2
  • Comments Comments (
    0
    ) |
dose4_1
  • Comments Comments (
    0
    ) |
dose4_2
  • Comments Comments (
    0
    ) |
duration4
  • Comments Comments (
    0
    ) |
admin4
  • Comments Comments (
    0
    ) |
comparator1 Placebo (maltodextrin)
  • Comments Comments (
    0
    ) |
cdose1 0.0
  • Comments Comments (
    0
    ) |
cduration1 8 weeks
  • Comments Comments (
    0
    ) |
cadmin1 Tablet
  • Comments Comments (
    0
    ) |
comparator2
  • Comments Comments (
    0
    ) |
cdose2
  • Comments Comments (
    0
    ) |
cduration2
  • Comments Comments (
    0
    ) |
cadmin2
  • Comments Comments (
    0
    ) |
comparator3
  • Comments Comments (
    0
    ) |
cdose3
  • Comments Comments (
    0
    ) |
cduration3
  • Comments Comments (
    0
    ) |
cadmin3
  • Comments Comments (
    0
    ) |
comparator4
  • Comments Comments (
    0
    ) |
cdose4
  • Comments Comments (
    0
    ) |
cduration4
  • Comments Comments (
    0
    ) |
cadmin4
  • Comments Comments (
    0
    ) |


Baseline Characteristics
No baseline characteristics have been defined for this extraction form.



Results & Comparisons

No Results found.
Adverse Events
Arm or Total Title Description Comments

Quality Dimensions
No quality dimensions were specified.

Quality Rating
No quality rating data was found.